[1]
Anderson JM, Moy L, Moy RL. Preventative Options and the Future of Chemoprevention for Cutaneous Tumors. Dermatologic clinics. 2023 Jan:41(1):231-238. doi: 10.1016/j.det.2022.07.020. Epub 2022 Oct 28
[PubMed PMID: 36410981]
[2]
Asgari MM, Moffet HH, Ray GT, Quesenberry CP. Trends in Basal Cell Carcinoma Incidence and Identification of High-Risk Subgroups, 1998-2012. JAMA dermatology. 2015 Sep:151(9):976-81. doi: 10.1001/jamadermatol.2015.1188. Epub
[PubMed PMID: 26039887]
[3]
Thompson AK, Kelley BF, Prokop LJ, Murad MH, Baum CL. Risk Factors for Cutaneous Squamous Cell Carcinoma Recurrence, Metastasis, and Disease-Specific Death: A Systematic Review and Meta-analysis. JAMA dermatology. 2016 Apr:152(4):419-28. doi: 10.1001/jamadermatol.2015.4994. Epub
[PubMed PMID: 26762219]
Level 1 (high-level) evidence
[4]
Guy GP Jr, Machlin SR, Ekwueme DU, Yabroff KR. Prevalence and costs of skin cancer treatment in the U.S., 2002-2006 and 2007-2011. American journal of preventive medicine. 2015 Feb:48(2):183-187. doi: 10.1016/j.amepre.2014.08.036. Epub 2014 Nov 10
[PubMed PMID: 25442229]
[5]
Desai S, Olbricht S, Ruiz ES, Hartman RI. Nicotinamide for Keratinocyte Carcinoma Chemoprevention: A Nationwide Survey of Mohs Surgeons. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]. 2021 Apr 1:47(4):452-453. doi: 10.1097/DSS.0000000000002788. Epub
[PubMed PMID: 33625146]
Level 3 (low-level) evidence
[6]
Snaidr VA, Damian DL, Halliday GM. Nicotinamide for photoprotection and skin cancer chemoprevention: A review of efficacy and safety. Experimental dermatology. 2019 Feb:28 Suppl 1():15-22. doi: 10.1111/exd.13819. Epub
[PubMed PMID: 30698874]
[7]
Forbat E, Al-Niaimi F, Ali FR. Use of nicotinamide in dermatology. Clinical and experimental dermatology. 2017 Mar:42(2):137-144. doi: 10.1111/ced.13021. Epub 2017 Jan 4
[PubMed PMID: 28052374]
[8]
Pang H, Xiao L, Lu Z, Chen H, Shang Z, Jiang N, Wang X, Wei F, Jiang A, Chen Y, Niu Y. Targeting androgen receptor in macrophages inhibits phosphate-induced vascular smooth muscle cell calcification by decreasing IL-6 expression. Vascular pharmacology. 2020 Jul:130():106681. doi: 10.1016/j.vph.2020.106681. Epub 2020 May 5
[PubMed PMID: 32387336]
[9]
Que SKT, Zwald FO, Schmults CD. Cutaneous squamous cell carcinoma: Management of advanced and high-stage tumors. Journal of the American Academy of Dermatology. 2018 Feb:78(2):249-261. doi: 10.1016/j.jaad.2017.08.058. Epub
[PubMed PMID: 29332705]
[10]
Chen AC, Martin AJ, Choy B, Fernández-Peñas P, Dalziell RA, McKenzie CA, Scolyer RA, Dhillon HM, Vardy JL, Kricker A, St George G, Chinniah N, Halliday GM, Damian DL. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. The New England journal of medicine. 2015 Oct 22:373(17):1618-26. doi: 10.1056/NEJMoa1506197. Epub
[PubMed PMID: 26488693]
Level 1 (high-level) evidence
[11]
Chen AC, Martin AJ, Dalziell RA, McKenzie CA, Lowe PM, Eris JM, Scolyer RA, Dhillon HM, Vardy JL, Bielski VA, Halliday GM, Damian DL. A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients. The British journal of dermatology. 2016 Nov:175(5):1073-1075. doi: 10.1111/bjd.14662. Epub 2016 Aug 10
[PubMed PMID: 27061568]
Level 1 (high-level) evidence
[12]
Allen NC, Martin AJ, Snaidr VA, Eggins R, Chong AH, Fernandéz-Peñas P, Gin D, Sidhu S, Paddon VL, Banney LA, Lim A, Upjohn E, Schaider H, Ganhewa AD, Nguyen J, McKenzie CA, Prakash S, McLean C, Lochhead A, Ibbetson J, Dettrick A, Landgren A, Allnutt KJ, Allison C, Davenport RB, Mumford BP, Wong B, Stagg B, Tedman A, Gribbin H, Edwards HA, De Rosa N, Stewart T, Doolan BJ, Kok Y, Simpson K, Low ZM, Kovitwanichkanont T, Scolyer RA, Dhillon HM, Vardy JL, Chadban SJ, Bowen DG, Chen AC, Damian DL. Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients. The New England journal of medicine. 2023 Mar 2:388(9):804-812. doi: 10.1056/NEJMoa2203086. Epub
[PubMed PMID: 36856616]
[13]
Mainville L, Smilga AS, Fortin PR. Effect of Nicotinamide in Skin Cancer and Actinic Keratoses Chemoprophylaxis, and Adverse Effects Related to Nicotinamide: A Systematic Review and Meta-Analysis. Journal of cutaneous medicine and surgery. 2022 May-Jun:26(3):297-308. doi: 10.1177/12034754221078201. Epub 2022 Feb 8
[PubMed PMID: 35134311]
Level 1 (high-level) evidence
[14]
McKerrow KJ, MacKie RM, Lesko MJ, Pearson C. The effect of oral retinoid therapy on the normal human immune system. The British journal of dermatology. 1988 Sep:119(3):313-20
[PubMed PMID: 2972309]
[15]
Bellman BA, Eaglstein WH, Miller J. Low dose isotretinoin in the prophylaxis of skin cancer in renal transplant patients. Transplantation. 1996 Jan 15:61(1):173
[PubMed PMID: 8560565]
[16]
Herold M, Good AJ, Nielson CB, Longo MI. Use of Topical and Systemic Retinoids in Solid Organ Transplant Recipients: Update and Review of the Current Literature. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]. 2019 Dec:45(12):1442-1449. doi: 10.1097/DSS.0000000000002072. Epub
[PubMed PMID: 31403546]
[17]
Kraemer KH, DiGiovanna JJ, Moshell AN, Tarone RE, Peck GL. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. The New England journal of medicine. 1988 Jun 23:318(25):1633-7
[PubMed PMID: 3287161]
[18]
Moshell AN. Prevention of skin cancer in xeroderma pigmentosum with oral isotretinoin. Cutis. 1989 May:43(5):485-90
[PubMed PMID: 2721244]
[19]
Lee JS, Park HS, Yoon HS, Cho S. Efficacy and Safety of Oral Alitretinoin in Hand Eczema and Palmoplantar Pustulosis in Korean Patients. Annals of dermatology. 2019 Apr:31(2):139-145. doi: 10.5021/ad.2019.31.2.139. Epub 2019 Feb 28
[PubMed PMID: 33911562]
[20]
Tsai DE, Aqui NA, Vogl DT, Bloom RD, Schuster SJ, Nasta SD, Wasik MA. Successful treatment of T-cell post-transplant lymphoproliferative disorder with the retinoid analog bexarotene. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2005 Aug:5(8):2070-3
[PubMed PMID: 15996263]
[21]
Lewis DJ, Huang S, Duvic M. Oral bexarotene for post-transplant cutaneous T-cell lymphoma. Dermatologic therapy. 2017 Sep:30(5):. doi: 10.1111/dth.12524. Epub 2017 Jul 26
[PubMed PMID: 28748653]
[22]
Que SKT, Zwald FO, Schmults CD. Cutaneous squamous cell carcinoma: Incidence, risk factors, diagnosis, and staging. Journal of the American Academy of Dermatology. 2018 Feb:78(2):237-247. doi: 10.1016/j.jaad.2017.08.059. Epub
[PubMed PMID: 29332704]
[23]
Knip M, Douek IF, Moore WP, Gillmor HA, McLean AE, Bingley PJ, Gale EA, European Nicotinamide Diabetes Intervention Trial Group. Safety of high-dose nicotinamide: a review. Diabetologia. 2000 Nov:43(11):1337-45
[PubMed PMID: 11126400]
[24]
Khalil S, Bardawil T, Stephan C, Darwiche N, Abbas O, Kibbi AG, Nemer G, Kurban M. Retinoids: a journey from the molecular structures and mechanisms of action to clinical uses in dermatology and adverse effects. The Journal of dermatological treatment. 2017 Dec:28(8):684-696. doi: 10.1080/09546634.2017.1309349. Epub 2017 Apr 2
[PubMed PMID: 28318351]
[25]
Nohynek GJ, Meuling WJ, Vaes WH, Lawrence RS, Shapiro S, Schulte S, Steiling W, Bausch J, Gerber E, Sasa H, Nau H. Repeated topical treatment, in contrast to single oral doses, with Vitamin A-containing preparations does not affect plasma concentrations of retinol, retinyl esters or retinoic acids in female subjects of child-bearing age. Toxicology letters. 2006 May 5:163(1):65-76
[PubMed PMID: 16243460]
Level 3 (low-level) evidence
[26]
Henning P, Conaway HH, Lerner UH. Retinoid receptors in bone and their role in bone remodeling. Frontiers in endocrinology. 2015:6():31. doi: 10.3389/fendo.2015.00031. Epub 2015 Mar 11
[PubMed PMID: 25814978]
[27]
Passi SF, Butcher R, Orme DR, Warner JEA, Stoddard GJ, Crum AV, Gouripeddi R, Kirk BH, Digre KB, Katz BJ. Increased Incidence of Pseudotumor Cerebri Syndrome Among Users of Tetracycline Antibiotics. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society. 2022 Sep 1:42(3):323-327. doi: 10.1097/WNO.0000000000001536. Epub 2022 Mar 25
[PubMed PMID: 35427251]
[29]
Altman RS, Altman LJ, Altman JS. A proposed set of new guidelines for routine blood tests during isotretinoin therapy for acne vulgaris. Dermatology (Basel, Switzerland). 2002:204(3):232-5
[PubMed PMID: 12037453]
[31]
Ludot M, Mouchabac S, Ferreri F. Inter-relationships between isotretinoin treatment and psychiatric disorders: Depression, bipolar disorder, anxiety, psychosis and suicide risks. World journal of psychiatry. 2015 Jun 22:5(2):222-7. doi: 10.5498/wjp.v5.i2.222. Epub
[PubMed PMID: 26110123]
[32]
Tan SR, Tope WD. Effect of acitretin on wound healing in organ transplant recipients. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]. 2004 Apr:30(4 Pt 2):667-73
[PubMed PMID: 15061853]
[33]
Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. The New England journal of medicine. 2003 Apr 24:348(17):1681-91
[PubMed PMID: 12711744]
[34]
Acuna SA, Fernandes KA, Daly C, Hicks LK, Sutradhar R, Kim SJ, Baxter NN. Cancer Mortality Among Recipients of Solid-Organ Transplantation in Ontario, Canada. JAMA oncology. 2016 Apr:2(4):463-9. doi: 10.1001/jamaoncol.2015.5137. Epub
[PubMed PMID: 26746479]
[35]
Euvrard S, Kanitakis J, Pouteil-Noble C, Dureau G, Touraine JL, Faure M, Claudy A, Thivolet J. Comparative epidemiologic study of premalignant and malignant epithelial cutaneous lesions developing after kidney and heart transplantation. Journal of the American Academy of Dermatology. 1995 Aug:33(2 Pt 1):222-9
[PubMed PMID: 7622649]
Level 2 (mid-level) evidence
[36]
Webb MC, Compton F, Andrews PA, Koffman CG. Skin tumours posttransplantation: a retrospective analysis of 28 years' experience at a single centre. Transplantation proceedings. 1997 Feb-Mar:29(1-2):828-30
[PubMed PMID: 9123544]
Level 2 (mid-level) evidence
[37]
Liddington M, Richardson AJ, Higgins RM, Endre ZH, Venning VA, Murie JA, Morris PJ. Skin cancer in renal transplant recipients. The British journal of surgery. 1989 Oct:76(10):1002-5
[PubMed PMID: 2597939]
[38]
Winkelhorst JT, Brokelman WJ, Tiggeler RG, Wobbes T. Incidence and clinical course of de-novo malignancies in renal allograft recipients. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2001 Jun:27(4):409-13
[PubMed PMID: 11417989]
[39]
Bavinck JN, De Boer A, Vermeer BJ, Hartevelt MM, van der Woude FJ, Claas FH, Wolterbeek R, Vandenbroucke JP. Sunlight, keratotic skin lesions and skin cancer in renal transplant recipients. The British journal of dermatology. 1993 Sep:129(3):242-9
[PubMed PMID: 8286220]
[40]
Kovach BT, Sams HH, Stasko T. Systemic strategies for chemoprevention of skin cancers in transplant recipients. Clinical transplantation. 2005 Dec:19(6):726-34
[PubMed PMID: 16313317]
[41]
Malesu R , Martin AJ , Lyons JG , Scolyer RA , Chen AC , McKenzie CA , Madore J , Halliday GM , Damian DL . Nicotinamide for skin cancer chemoprevention: effects of nicotinamide on melanoma in vitro and in vivo. Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology. 2020 Feb 19:19(2):171-179. doi: 10.1039/c9pp00388f. Epub
[PubMed PMID: 31942903]
[42]
Goodson AG, Cotter MA, Cassidy P, Wade M, Florell SR, Liu T, Boucher KM, Grossman D. Use of oral N-acetylcysteine for protection of melanocytic nevi against UV-induced oxidative stress: towards a novel paradigm for melanoma chemoprevention. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Dec 1:15(23):7434-40. doi: 10.1158/1078-0432.CCR-09-1890. Epub 2009 Nov 17
[PubMed PMID: 19920101]
[43]
Murray SL, Daly FE, O'Kelly P, O'Leary E, Deady S, O'Neill JP, Dudley A, Rutledge NR, McCormick A, Houlihan DD, Williams Y, Morris PG, Ni Raghallaigh S, Moloney FJ, Sexton DJ, Conlon PJ. The impact of switching to mTOR inhibitor-based immunosuppression on long-term non-melanoma skin cancer incidence and renal function in kidney and liver transplant recipients. Renal failure. 2020 Nov:42(1):607-612. doi: 10.1080/0886022X.2020.1785499. Epub
[PubMed PMID: 32605413]
[44]
Euvrard S, Boissonnat P, Roussoulières A, Kanitakis J, Decullier E, Claudy A, Sebbag L. Effect of everolimus on skin cancers in calcineurin inhihitor-treated heart transplant recipients. Transplant international : official journal of the European Society for Organ Transplantation. 2010 Aug:23(8):855-7. doi: 10.1111/j.1432-2277.2009.01010.x. Epub 2009 Nov 27
[PubMed PMID: 19951373]
[45]
Campbell SB, Walker R, Tai SS, Jiang Q, Russ GR. Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2012 May:12(5):1146-56. doi: 10.1111/j.1600-6143.2012.04004.x. Epub 2012 Mar 15
[PubMed PMID: 22420843]
Level 1 (high-level) evidence
[46]
Yakupoglu YK, Buell JF, Woodle S, Kahan BD. Individualization of immunosuppressive therapy. III. Sirolimus associated with a reduced incidence of malignancy. Transplantation proceedings. 2006 Mar:38(2):358-61
[PubMed PMID: 16549120]